快樂小藥師 Im pharmacist nichts glücklich

今天收到MIMS寄來的信，標題是：The Role of DPP-4 Inhibitor/Metformin Fixed-Dose Combinations in Treating Type 2 Diabetes Mellitus

Diabetes mellitus (DM) is a global epidemic, and most patients in Asia have poor glycaemic control. Dipeptidyl peptidase-4 (DPP-4) inhibitors are new additions to the antidiabetic drug arsenal. More recently, these compounds have become available as fixed-dose combinations with metformin. In this paper, we examine the clinical effects of these compounds and discuss their role in the management of type 2 DM.

詳細說明其實是PDF檔，不過我懶得轉檔了，大家自己看吧

http://www.mims.com/document/MP-08%20DrugProfile.pdf

懶得下載的可以直接看結論：

The attainment of optimal glycaemic targets (HbA1C <7%) is an important goal in treating T2DM, in order to

reduce the morbidity and mortality associated with the disease. DPP-4 inhibitors offer a novel therapeutic

strategy which results in improved glycaemic control, without the increased risk of hypoglycaemia or weight gain.

In existing treatment paradigms, the DPP-4 inhibitors represent a reasonable choice to add on when blood

glucose is not optimally controlled with metformin and lifestyle modification.

This is particularly true in patients in whom the goals of minimizing hypoglycaemia and weight gain are important. The use of fixed-dose combinations of DPP-4 inhibitors/metformin may be useful in this context. If beta-cell preservation is proven clinically in humans in future, it will be useful for newly diagnosed patients. However, the long-term safety of DPP-4 inhibitors remains to be seen.